I used to do antibiotic drug discovery for a living. You hit the nail on the head.
I'll go so far as to say that we've found all of the important bacterial targets (e.g., ribosome, peptidoglycan, DNA gyrase & a few others).
That's probably an overstatement....but I (and many others) spent a large amount of time/$/effort looking for antibacterial targets that might have been overlooked. In the end, my conclusion was that we've already found the softest, most vulnerable targets within bacteria and we've known about them for a long time.
What to do? I think 2 things. Find new ways to hit the existing validated targets (people are doing this, but it ain't easy). The only other "idea" that I've had (and I'm sure others have had it, too), is that maybe we can find multiple "weak" targets that, when hit in combination, are just as good at inactivating a single "thing" like the bacterial ribosome. But that's probably even more difficult than finding new ways to hit well-validated targets.
I'll go so far as to say that we've found all of the important bacterial targets (e.g., ribosome, peptidoglycan, DNA gyrase & a few others).
That's probably an overstatement....but I (and many others) spent a large amount of time/$/effort looking for antibacterial targets that might have been overlooked. In the end, my conclusion was that we've already found the softest, most vulnerable targets within bacteria and we've known about them for a long time.
What to do? I think 2 things. Find new ways to hit the existing validated targets (people are doing this, but it ain't easy). The only other "idea" that I've had (and I'm sure others have had it, too), is that maybe we can find multiple "weak" targets that, when hit in combination, are just as good at inactivating a single "thing" like the bacterial ribosome. But that's probably even more difficult than finding new ways to hit well-validated targets.